logo
State Seasonal Disease Monitoring Officer Reviews Preparedness in Jogulamba Gadwal to Combat Dengue, Malaria, and Chikungunya

State Seasonal Disease Monitoring Officer Reviews Preparedness in Jogulamba Gadwal to Combat Dengue, Malaria, and Chikungunya

Hans Indiaa day ago
Gadwal: Dr. Sudhakar Lal, the State Seasonal Disease Monitoring Officer, visited Jogulamba Gadwal district today to review the status and preparedness regarding seasonal diseases. A review meeting was held at the District Medical and Health Office, where he was joined by District Medical and Health Officer Dr. S.K. Siddappa, along with district program officers, PHC (Primary Health Centre) medical officers, and supervisors.
Focus of the Review Meeting:
The review primarily focused on the district's preparedness to prevent and control seasonal vector-borne diseases such as:
Dengue
Malaria
Chikungunya
Dr. Sudhakar Lal emphasized the importance of taking preventive measures proactively to avoid outbreaks. He directed that in areas where such diseases are reported, District Rapid Response Teams (RRTs) and PHC-level RRTs must conduct field visits and implement anti-larval measures and anti-malaria interventions immediately.
Key Directives Issued:
Dry Day activities must be conducted in every village every Friday to eliminate mosquito breeding grounds.
Areas affected by dengue last year, and identified high-risk villages, must be prioritized.
Medical camps should be organized in such locations to create awareness and provide early treatment.
Public awareness campaigns must be intensified to educate people on prevention, symptoms, and early reporting of these diseases.
Officials in Attendance:
Several key officials participated in the meeting, including:
Dr. Sandya Kiranmai – NCD Program Officer
Dr. G. Raju – NCVBDC Program Officer
Dr. Rizwana – District Immunization Officer
Dr. Prasoona Rani – MHN Program Officer
Dr. K. Madhusudhan Reddy – Deputy DM&HO
B. Sivanna – Senior Surveillance Officer (SUO)
Narendrababu – District Vector-Borne Disease Control Program Officer (DVLM)
T. Varalaxmi – DPHNO
Rama Anjaneyulu – DDM
K. Shyam Sundar – District NCD Coordinator
PHC Medical Officers and other health department staff
Conclusion:
The visit and subsequent meeting underscored the government's commitment to preventing seasonal disease outbreaks through early intervention, village-level awareness, and coordinated efforts across departments. The emphasis on community engagement and timely action is expected to significantly reduce the risk and impact of seasonal diseases in the district.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues
Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Time of India

time14 hours ago

  • Time of India

Sun Pharma, Lupin, Dr Reddy's recall products in US market due to manufacturing issues

Domestic drug majors Sun Pharma , Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator . As per the latest Enforcement Report of US Food and Drug Administration ( USFDA), ), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Explore courses from Top Institutes in Please select course: Select a Course Category PGDM Operations Management MBA others Data Analytics Cybersecurity Public Policy Management Healthcare Design Thinking MCA Data Science Data Science Product Management Others Artificial Intelligence Degree Project Management Digital Marketing Technology Leadership CXO healthcare Finance Skills you'll gain: Financial Analysis & Decision Making Quantitative & Analytical Skills Organizational Management & Leadership Innovation & Entrepreneurship Duration: 24 Months IMI Delhi Post Graduate Diploma in Management (Online) Starts on Sep 1, 2024 Get Details Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to "Failed Dissolution Specifications", the US health regulator stated. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like How Much Does It Cost to Rent a Private Jet - The Prices May Surprise You! Private Jet I Search Ads Learn More Undo The medication is used to treat attention deficit hyperactivity disorder ( ADHD ). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Live Events Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to "Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy 's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories , Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal.

Sun Pharma, Lupin, Dr Reddys recall products in US market
Sun Pharma, Lupin, Dr Reddys recall products in US market

News18

time14 hours ago

  • News18

Sun Pharma, Lupin, Dr Reddys recall products in US market

New Delhi, Jul 27 (PTI) Domestic drug majors Sun Pharma, Lupin and Dr Reddy's Laboratories are recalling drugs in the US market due to manufacturing issues and product mix up, according to the US health regulator. As per the latest Enforcement Report of US Food and Drug Administration (USFDA), the Mumbai-headquartered Sun Pharmaceutical Industries is recalling 5,448 bottles of a generic medication in the US. Princeton-based Sun Pharmaceutical Industries Inc is recalling the affected lot of Lisdexamfetamine Dimesylate capsules (60 mg) due to 'Failed Dissolution Specifications", the US health regulator stated. The medication is used to treat attention deficit hyperactivity disorder (ADHD). The drug firm initiated the Class II recall in the US on June 16 this year, it added. Another Mumbai-based drug maker Lupin is recalling 58,968 bottles of a generic combination medication used to treat high blood pressure. Naples-based Lupin Pharmaceuticals Inc is recalling Lisinopril and Hydrochlorothiazide tablets (USP 20mg/12.5mg). The affected lot was manufactured at the company's Nagpur-based manufacturing facility. As per the USFDA, the company initiated the Class II recall on June 20 due to 'Product Mix Up". This product is being recalled because of a complaint received that a sealed bottle of lisinopril and hydrochlorothiazide tablets 20mg/12.5 mg had a foreign tablet identified as atazanavir and ritonavir tablet 300mg/100mg, the US health regulator stated. In another filing, the US health regulator said that Dr Reddy's Laboratories is recalling 1,476 bottles of Omeprazole Delayed-release capsules. The medication is used to treat certain stomach and esophagus problems. Princeton-based Dr. Reddy's Laboratories, Inc initiated the Class II recall on June 30, 2025, USFDA stated. The affected lot was produced at the company's Bachupally (Telangana)-based manufacturing facility. The recall is due to the presence of foreign tablets/capsules, USFDA said. It is due to the presence of foreign Divalproex Sodium extended-release 250mg tablets in a bottle of omeprazole capsules, it added. As per the USFDA, a Class-II recall is initiated when the use of, or exposure to, a violative product may lead to temporary or medically reversible health consequences, or when the likelihood of serious adverse health outcomes is minimal. PTI MSS HVA view comments First Published: July 27, 2025, 10:45 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.

NT RUHS invites applications for MBBS management quota for 2025-26
NT RUHS invites applications for MBBS management quota for 2025-26

New Indian Express

time16 hours ago

  • New Indian Express

NT RUHS invites applications for MBBS management quota for 2025-26

VIJAYAWADA: Dr NTR University of Health Sciences (NT RUHS), Vijayawada, has issued a notification inviting online applications for admissions into MBBS and BDS courses under the Management Quota for the academic year 2025-26. The seats include Category-B1, B2, and Category-C (NRI) in private unaided non-minority and minority medical and dental colleges, along with NRI seats at Sri Padmavathi Medical College for Women under SVIMS, Tirupati. Candidates who qualified NEET-UG 2025 with the required cutoff scores are eligible to apply. The application window without a late fee is open from 9 AM on July 28 to 9 PM on August 2. With a late fee of Rs 20,000, applications will be accepted until August 4, 9 PM. The total fee with late submission is Rs 30,620 including GST. Applicants must upload scanned originals of the NEET-UG rank card, SSC and intermediate marksheets, study and caste certificates (if applicable), and valid identity for NRI quota seats must submit a declaration and documents validating NRI status. The eligibility criteria include a minimum of 50% marks in Physics, Chemistry, and Biology in the qualifying exam (40% for reserved categories) and completion of 17 years of age by December 31. Applicants are advised to read the prospectus on the official websites or https:// in.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store